title: Eletriptan Pfizer.
abstract: Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].
authors.affiliation: Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Avenue, Harlow, Essex, CM19 5AD, UK. Paul_J_Strijbos@GSK.com
authors.forename: Paul J L M
authors.initials: PJ
authors.lastname: Strijbos
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Parsons
authors.forename: Anders
authors.initials: A
authors.lastname: Fugelli
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D014363:Tryptamines
chemical_list: D007211:Indoles; D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C115647:eletriptan